Although it is not a contraindication to use GLP-1 RAs in people with a history of pancreatitis, the summary of product characteristics of these therapies have included warnings concerning the risk of acute pancreatitis [16, 18, 20, 22, 24, 26, 28]
This may mean: Some people will need slower dose escalation Patients with lower BMIs may not tolerate it well Doctors will need to monitor symptoms closely It could reshape treatment pathways If approved by the FDA and MHRA, retatrutide may be recommended for: People needing large, rapid weight loss Those with severe obesity Patients with obesity-related complications More moderate cases may still be better suited to GLP-1-only or dual-agonist medications
[DOI] [PMC free article] [PubMed] [Google Scholar] 15.Goyal N.P., Schwimmer J.B
We have many patients who opt for dual therapy at some point during their treatment
Deferred interest means interest accrues from day one but is not charged to your account as long as you pay off the full balance within the promotional period
